血液科指南

订阅

MedSci主页 / 所有栏目 / 血液科指南

2020 BSH指南：儿童和成人血友病A和B的预防性因子替代治疗

2020-05-10 英国血液病学学会 Br J Haematol . 2020 May 10.

血友病

2020年5月，英国血液病学学会(BSH)发布了儿童和成人血友病A和B的预防性因子替代治疗指南，血友病 (PWH)A或B患者定期接受凝血因子替代治疗可按需治疗也可预防治疗。本文主要针对儿童和成人血友病

中文标题：

2020 BSH指南：儿童和成人血友病A和B的预防性因子替代治疗

英文标题：

Guidelines on the Use of Prophylactic Factor Replacement for Children and Adults With Haemophilia A and B

发布机构：

英国血液病学学会

发布日期：

2020-05-10

简要介绍：

2020年5月，英国血液病学学会(BSH)发布了儿童和成人血友病A和B的预防性因子替代治疗指南，血友病 (PWH)A或B患者定期接受凝血因子替代治疗可按需治疗也可预防治疗。本文主要针对儿童和成人血友病A和B的预防性因子替代治疗提供指导建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 BSH指南：儿童和成人血友病A和B的预防性因子替代治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=32ef21c0019366b7, title=2020 BSH指南：儿童和成人血友病A和B的预防性因子替代治疗, enTitle=Guidelines on the Use of Prophylactic Factor Replacement for Children and Adults With Haemophilia A and B, guiderFrom=Br J Haematol . 2020 May 10., authorId=0, author=, summary=2020年5月，英国血液病学学会(BSH)发布了儿童和成人血友病A和B的预防性因子替代治疗指南，血友病 (PWH)A或B患者定期接受凝血因子替代治疗可按需治疗也可预防治疗。本文主要针对儿童和成人血友病, cover=https://img.medsci.cn/2020717/1594967168205_2020535.jpg, journalId=0, articlesId=null, associationId=1339, associationName=英国血液病学学会, associationIntro=, copyright=0, guiderPublishedTime=Sun May 10 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年5月，英国血液病学学会(BSH)发布了儿童和成人血友病A和B的预防性因子替代治疗指南，血友病 (PWH)A或B患者定期接受凝血因子替代治疗可按需治疗也可预防治疗。本文主要针对儿童和成人血友病A和B的预防性因子替代治疗提供指导建议。</p> </div> </div> </div>, tagList=[TagDto(tagId=1541, tagName=血友病)], categoryList=[CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1541, guiderKeyword=血友病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2853, appHits=135, showAppHits=0, pcHits=414, showPcHits=2718, likes=4, shares=24, comments=6, approvalStatus=1, publishedTime=Fri Jul 17 15:03:30 CST 2020, publishedTimeString=2020-05-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Fri Jul 17 14:26:15 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Thu Jan 04 13:33:26 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 BSH指南：儿童和成人血友病A和B的预防性因子替代治疗.pdf)])
2020 BSH指南：儿童和成人血友病A和B的预防性因子替代治疗.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=953562, encodeId=5ad395356217, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210409/24a3c88bf27e42c89be15f164e992883/47fd023e77434094b3d596b55574979b.jpg, createdBy=7d082543841, createdName=12528eb6m08暂无昵称, createdTime=Sat Apr 03 16:20:18 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889097, encodeId=229788909ebe, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57745264555, createdName=1480cb17m32暂无昵称, createdTime=Tue Sep 29 10:13:33 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803498, encodeId=6c9280349854, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Mon Jul 20 15:24:32 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803491, encodeId=6bad803491fb, content=怎么看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/2225a1016c68452e83e3cf81e3c1eebc/88616892eebd49e6a91409f49f74b121.jpg, createdBy=85955401667, createdName=冲锋龙马马, createdTime=Mon Jul 20 15:14:30 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2021-04-03 12528eb6m08暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=953562, encodeId=5ad395356217, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210409/24a3c88bf27e42c89be15f164e992883/47fd023e77434094b3d596b55574979b.jpg, createdBy=7d082543841, createdName=12528eb6m08暂无昵称, createdTime=Sat Apr 03 16:20:18 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889097, encodeId=229788909ebe, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57745264555, createdName=1480cb17m32暂无昵称, createdTime=Tue Sep 29 10:13:33 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803498, encodeId=6c9280349854, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Mon Jul 20 15:24:32 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803491, encodeId=6bad803491fb, content=怎么看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/2225a1016c68452e83e3cf81e3c1eebc/88616892eebd49e6a91409f49f74b121.jpg, createdBy=85955401667, createdName=冲锋龙马马, createdTime=Mon Jul 20 15:14:30 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2020-09-29 1480cb17m32暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=953562, encodeId=5ad395356217, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210409/24a3c88bf27e42c89be15f164e992883/47fd023e77434094b3d596b55574979b.jpg, createdBy=7d082543841, createdName=12528eb6m08暂无昵称, createdTime=Sat Apr 03 16:20:18 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889097, encodeId=229788909ebe, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57745264555, createdName=1480cb17m32暂无昵称, createdTime=Tue Sep 29 10:13:33 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803498, encodeId=6c9280349854, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Mon Jul 20 15:24:32 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803491, encodeId=6bad803491fb, content=怎么看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/2225a1016c68452e83e3cf81e3c1eebc/88616892eebd49e6a91409f49f74b121.jpg, createdBy=85955401667, createdName=冲锋龙马马, createdTime=Mon Jul 20 15:14:30 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2020-07-20 ms7000001773953003

    谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=953562, encodeId=5ad395356217, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210409/24a3c88bf27e42c89be15f164e992883/47fd023e77434094b3d596b55574979b.jpg, createdBy=7d082543841, createdName=12528eb6m08暂无昵称, createdTime=Sat Apr 03 16:20:18 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889097, encodeId=229788909ebe, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57745264555, createdName=1480cb17m32暂无昵称, createdTime=Tue Sep 29 10:13:33 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803498, encodeId=6c9280349854, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Mon Jul 20 15:24:32 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803491, encodeId=6bad803491fb, content=怎么看不了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/2225a1016c68452e83e3cf81e3c1eebc/88616892eebd49e6a91409f49f74b121.jpg, createdBy=85955401667, createdName=冲锋龙马马, createdTime=Mon Jul 20 15:14:30 CST 2020, time=2020-07-20, status=1, ipAttribution=)]
    2020-07-20 冲锋龙马马

    怎么看不了

    0

相关指南

血友病治疗中国指南（2020年版）

中华医学会血液学分会血栓与止血学组 · 2020-04-30

2020 国际建议：获得性血友病A的诊断和治疗

国外血液科相关专家小组 · 2020-05-07

2020 法国指南：血友病患者输注后因子VIII和IX监测

国外血液科相关专家小组 · 2020-04-10

2019 UKHCDO指南：艾美赛珠单抗治疗与实验室凝血检测

暂未更新 · 2019-12-20

2019 意大利共识：血友病患者的实验室检测

意大利血瘀血栓学会(SISET,Italian Society for Haemostasis and Thrombosis) · 2019-02-04

2018 专家共识：血友病患者早期肌肉骨骼疾病评估

国外血液科相关专家小组 · 2018-07-16

拓展阅读

2014 获得性血友病A诊断与治疗中国专家共识

中华医学会血液学分会血栓与止血学组 · 2014-06-15

MASAC建议：血友病患者的肝活组织检查（2013年）

国家血友病基金会医学科学咨询委员会(MASAC,Medical and Scientific Advisory Council of the National Hemophilia Foundation) · 2016-06-08

2015 UKHCDO指南：血友病临床遗传学服务

暂未更新 · 2015-05-01

【专题】 改善生命质量，携手对抗罕见病十周年：2.28国际罕见病指南合集

暂未更新 · 2017-02-28

中国儿童血友病专家指导意见（2017年）

中华医学会血液学分会血栓与止血学组 · 2017-01-30

《中国儿童血友病专家指导意见（2017年）》解读

暂未更新 · 2017-01-30